Brief: Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update

Intercept Pharmaceuticals

01/11/2022 11:14

Nov 1 (Reuters) - Intercept Pharmaceuticals Inc
 ICPT.O :
    * INTERCEPT PHARMACEUTICALS REPORTS THIRD QUARTER 2022
FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
    * Q3 SALES ROSE 16.4 PERCENT TO $77.6 MILLION
    * INTERCEPT - AS OF SEPT 30, 2022, CO HAS CASH, CASH
EQUIVALENTS,
RESTRICTED CASH, AND INVESTMENT DEBT SECURITIES AVAILABLE FOR
SALE OF $497.8 MILLION
    * INTERCEPT - ON TRACK TO RESUBMIT NDA FOR OBETICHOLIC ACID
IN
LIVER FIBROSIS DUE TO NASH BY END OF 2022 BASED ON POSITIVE
PHASE 3 REGENERATE STUDY
    * INCREASES 2022 OCALIVA NON-GAAP ADJUSTED NET SALES
GUIDANCE TO
$340 MILLION TO $350 MILLION
    * NARROWS 2022 NON-GAAP ADJUSTED OPERATING EXPENSE GUIDANCE
TO
$350 MILLION TO $365 MILLION
    * QTRLY U.S. OCALIVA NET SALES OF $77.6 MILLION
    * Q3 EARNINGS PER SHARE VIEW $4.61, REVENUE VIEW $74.1
MILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID:nGNXcbTNw7 
Further company coverage:  ICPT.O 
 ((Reuters.Briefs@thomsonreuters.com;))